Literature DB >> 19468681

Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.

Andre C Felicio1, Clecio Godeiro-Junior, Patricia de Carvalho Aguiar, Vanderci Borges, Sonia M A Silva, Henrique B Ferraz.   

Abstract

We retrospectively evaluated 118 patients with cervical dystonia (CD) treated with botulinum toxin type A (BTX-A) for the following variables: gender, age at evaluation, age at symptom onset, disease duration, presence of head/neck pain and/or tremor, pattern of head deviation, disease progression (spreading of symptoms), etiology (primary vs. secondary), pretreatment with oral medication, and Tsui score. We investigated whether these parameters could predict the clinical outcome in a short- (<30 days) and long-term basis. On short-term treatment, there were no clinically significant differences between BTX-A responsive and non-responsive patients. On long-term treatment, however, intake of oral medication previously to BTX-A injection and higher Tsui scores were predictors of favorable response. These results suggest that the greater CD severity the more likely patients will respond to BTX-A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19468681     DOI: 10.1007/s10072-009-0097-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  15 in total

1.  Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.

Authors:  Peter Haussermann; Stefanie Marczoch; Christiane Klinger; Michael Landgrebe; Bastian Conrad; Andres Ceballos-Baumann
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

Review 2.  Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

Review 3.  Treatment of cervical dystonia with botulinum toxin.

Authors:  Joseph Jankovic
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

Review 4.  The treatment of cervical dystonia with botulinum toxins.

Authors:  C L Comella
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

5.  Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors.

Authors:  Spiridon Papapetropoulos; Sheila Baez; Jennifer Zitser; Cenk Sengun; Carlos Singer
Journal:  Eur Neurol       Date:  2007-10-04       Impact factor: 1.710

6.  Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.

Authors:  D Tarsy
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

7.  Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.

Authors:  K R Kessler; M Skutta; R Benecke
Journal:  J Neurol       Date:  1999-04       Impact factor: 4.849

8.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

9.  Motion analysis in cervical dystonia.

Authors:  Cristina Boccagni; Jacopo Carpaneto; Silvestro Micera; Sergio Bagnato; Giuseppe Galardi
Journal:  Neurol Sci       Date:  2008-11-29       Impact factor: 3.307

10.  Clinical comparison of tardive and idiopathic cervical dystonia.

Authors:  E S Molho; P J Feustel; S A Factor
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

View more
  1 in total

Review 1.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.